Immunome Inc. 8-K

What Happened
Immunome, Inc. announced its financial results for the year ended December 31, 2025 and provided a business update in a press release filed on March 3, 2026. The company disclosed this information in an 8‑K under Item 2.02 (Results of Operations and Financial Condition) and attached the press release as Exhibit 99.1.

Key Details

• Filing date: March 3, 2026 (Form 8‑K).
• Reporting period: year ended December 31, 2025.
• Press release: Exhibit 99.1 contains the full announcement and business update.
• Administrative items: Inline XBRL cover page included (Exhibit 104); 8‑K signed by CFO Max Rosett.

Why It Matters
This 8‑K signals that Immunome has released its annual financial results and any accompanying operational updates — information investors use to evaluate revenue, expenses, cash position, and strategic progress. Retail investors should read the attached press release (Exhibit 99.1) and the company’s subsequent or accompanying SEC filings for the specific financial figures, guidance, and any changes to operations or outlook that could affect the stock.